The FDA has approved AbbVie’s Gonadotropin-Releasing Hormone (GnRH) antagonist Elagolix on Tuesday. FDA has given green light to the first oral treatment for endometriosis pain. The drug is branded as Orilissa, and is expected to be available in U.S. pharmacies in August. It will carry a list price of about $850 per month, or just over $10,100 per year. Abbott paid $75 million and agreed to pay $500 million in development process. The drug cost watchdog, also stated in the June report that the drug can still tax the healthcare system based on the number of women affected with endometriosis. Orilissa is one of the new drugs to hit the market for endometriosis pain. There are two other drugs in late-stages, as well as 11 drugs in the mid-stage pipeline.
DelveInsight Blog
Related Article
SIBIONICS’s Ground-breaking GS1 Continuous Glucose Monitoring System; Abbott’s HPV Test to Run on Alinity m; CleanNA’s CE-IVD Molecular Diagnostics Product; Orthofix’s WaveForm L Interbody System; Alucent Biomedical’s AlucentNVS Technology; Surmodics’s TRANSCEND Trial Data
SIBIONICS Received CE Mark for Its Ground-breaking GS1 Continuous Glucose Monitoring System On November 01, 2023, SIBIONICS, the world's third-largest Continuous Glucose Monitoring System (CGM) brand, received the CE Mark for its revolutionary GS1 CGM. This significant milestone marks a momentous achiev...
Find More
Cardio Flow’s FreedomFlow Orbital Atherectomy Peripheral Platform; Medtronic’s Aurora EV- ICD System to Treat Arrhythmias; GE Healthcare and Novo Nordisk Announces Collaboration; Olympus’s EVIS X1 Endoscopy System; Medtronic’s Evolut TAVR Platform Outperformed Surgery with Sustained Valve Performance; Abbott’s Minimally Invasive Devices for People with Leaky Heart Valves
Olympus Announced Market Launch of EVIS X1™ Endoscopy System On October 19, 2023, Olympus Corporation, a global medical technology company announced the market launch of its next-generation EVIS X1™ endoscopy system. The GIF-1100 gastrointestinal videoscope indicated for use in the upper digestive tract, and ...
Find More
Enovis Acquires Novastep; Rockwell Medical Announced Collaboration with B. Braun; Dexcom G7 Received Health Canada Approval for Next-Generation CGM; Abbott’s World’s First Dual Chamber Leadless Pacemaker; Elios Vision’s Pivotal Trial of ELIOS; Synergy Spine’s Synergy Disc 2-Level IDE Trial
Enovis completed the acquisition of Novastep On June 29, 2023, Enovis, one of the largest orthopedic device companies in the world, announced that the company had completed the purchase of Novastep and its foot and ankle minimally invasive surgical (MIS) platform, which was first announced in April 2023. ...
Find MoreEditor's Pick
Newsletter/Whitepaper
-Agonist.png "Toll-like Receptors Agonist")
Recent Article
ASCO Conference 2023
The American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.